Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CT-2103: emerging utility and therapy for solid tumours.

Corey J Langer1

  • 1Fox Chase Cancer Center, Thoracic Oncology, Philadelphia, PA 19111, USA. CJ_Langer@fccc.edu

Expert Opinion on Investigational Drugs
|October 27, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461].

The journal of liquid biopsy·2026
Same author

Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study.

Frontiers in oncology·2026
Same author

The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing.

The journal of liquid biopsy·2026
Same author

Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy.

American journal of clinical oncology·2025
Same author

The influence of body mass index on Tumor Treating Fields therapy in patients with metastatic non-small cell lung cancer: A post-hoc and simulation analysis from the phase III LUNAR study.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAF<sup>V600E</sup>-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study.

The Lancet. Oncology·2025
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

CT-2103, a paclitaxel conjugate, shows enhanced tumor penetration and activity compared to standard paclitaxel. This novel agent offers potential for improved efficacy and reduced toxicity in various solid tumors, including lung and ovarian cancers.

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Delivery

Background:

  • Paclitaxel is a widely used chemotherapy agent, but its efficacy can be limited by its administration vehicle (Cremophor EL) and associated toxicities.
  • CT-2103 (XYOTAX) is a novel conjugate of paclitaxel to a polyglutamate polymer, designed to improve tumor targeting and drug release.
  • The macromolecular nature of CT-2103 enhances its permeability and retention in tumor tissues, while its unique formulation avoids the need for Cremophor EL.

Purpose of the Study:

  • To evaluate the pharmacokinetic, biodistribution, and antitumor activity of CT-2103 in preclinical models.
  • To assess the safety and tolerability of CT-2103 in early-phase clinical trials.
  • To investigate the efficacy of CT-2103 in patients with non-small cell lung carcinoma (NSCLC) and ovarian cancer.

Main Methods:

Related Experiment Videos

  • Preclinical studies compared CT-2103 to unconjugated paclitaxel in terms of plasma and tumor pharmacokinetics and efficacy in various tumor models.
  • Phase I clinical trials assessed the safety, tolerability, and maximum tolerated dose (MTD) of CT-2103, both as a single agent and in combination with carboplatin.
  • Phase II and III clinical trials are ongoing to evaluate CT-2103 efficacy in NSCLC and ovarian cancer patients, comparing it against standard chemotherapy regimens.

Main Results:

  • Preclinical studies demonstrated a >12-fold increase in the area under the curve for CT-2103 in plasma and tumor tissue compared to paclitaxel, with enhanced antitumor activity, including in paclitaxel-resistant models.
  • Phase I trials indicated that CT-2103 is relatively well-tolerated, with acceptable toxicity at doses up to 225 mg/m(2) every 3 weeks. The MTD with carboplatin was 235 mg/m(2).
  • Clinical activity has been observed in NSCLC and ovarian cancer, leading to ongoing Phase III trials comparing CT-2103 to paclitaxel in ovarian cancer maintenance therapy and Phase II trials comparing it to docetaxel in second-line NSCLC treatment.

Conclusions:

  • CT-2103 exhibits a favorable pharmacokinetic profile and enhanced antitumor activity compared to conventional paclitaxel in preclinical settings.
  • The agent demonstrates acceptable safety and tolerability in early clinical trials, suggesting a potential for improved therapeutic index.
  • Ongoing clinical trials will further define the role of CT-2103 in the treatment of solid tumors, particularly NSCLC and ovarian cancer, potentially offering a new therapeutic option.